On May

The information under Item 2.02 in this current report on Form 8-K and the related information in the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.

Item 9.01. Financial Statements and Exhibits.

(d)     Exhibits

Exhibit No.

Description

99.1

Press Release dated May 10, 2021

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to b e signed on its behalf by the undersigned hereunto duly authorized.

SEER, INC.

May 10, 2021

/s/ David Horn

David Horn

Chief Financial Officer

Ex. 99.1

Seer Reports First Quarter 2021 Financial Results

Second Phase of Commercialization Advances with the Addition of Multiple Limited Release Customers

REDWOOD CITY, Calif.

May 10, 2021 – Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the first quarter ended March 31, 2021.

“I am so incredibly proud of and amazed by our team for the progress we have made this quarter,” said Omid Farokhzad, Chair and Chief Executive Officer. “Unbiased, deep, rapid proteomics at scale will pave the way for broad-scale and novel biological insight – with incredible impact across science and medicine. We look forward to continuing to build our commercial momentum throughout 2021 as we bring the next phase in omics to labs around the globe.”

Recent Highlights

Advanced phase two of our three-phase commercial plan by signing agreements with multiple Limited Release customers

Completed installation at Salk Institute, bringing total number of active collaboration sites to four

OHSU Knight Cancer Institute and the Broad Institute successfully completed their initial pilot studies and are progressing toward larger-scale follow-on studies

Strengthened leadership team with the addition of Kenny Ross as VP Operations and Quality

Doubled the size of Redwood City headquarters with a new lease to support growing organization

First Quarter 2021 Financial Results

Revenue was $62,000 for the three months ended March 31, 2021, as compared to $177,000 for the three months ended March 31, 2020. The decrease was due to less activity associated with our Small Business Innovation Research grant from the NIH.

Operating expenses were $16.6 million for the first quarter of 2021, as compared to $6.0 million for the corresponding prior year period. The increase in expenses was driven by higher employee compensation costs and other expenses related to being a publicly traded company, as well as an increase in product development expenses related to our Proteograph Product Suite.

Net loss was $16.4 million for the first quarter of 2021, as compared to $5.5 million for the corresponding prior year period.

Cash, cash equivalents and investments were approximately $531 million as of March 31, 2021.

Webcast Information

Seer will host a conference call to discuss the first quarter 2021 financial results on Monday, May 10, 2021 at 1:30 pm Pacific Time / 4:30 pm Eastern Time. A webcast of the conference call can be accessed at http://investor.seer.bio. The webcast will be archived and available for replay for at least 90 days after the event.

About Seer

Seer is a life sciences company developing transformative products that open up a new gateway to the proteome. Seer is commercializing its Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform deep, unbiased proteomic analysis at scale in a matter of hours. Seer designed the Proteograph workflow to be efficient and easy-to-use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution that can be adopted by nearly any lab. Seer’s Proteograph Product Suite is for research use only and is not intended for diagnostic procedures.

For more information, please visit www.seer.bio.

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements are based on the Company’s beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements, including but not limited to statements regarding our timing and ability to enable unbiased, deep and rapid proteomics available at scale. These and other risks are described more fully in the Company’s filings with the Securities and Exchange Commission (“SEC”), including the Company’s Quarterly Report on Form 10-Q, to be filed with the SEC on May 10, 2021, and other documents the Company subsequently files with the SEC from time to time. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Investor Contact:

Carrie Mendivil

investor@seer.bio

Media Contact:

Karen Possemato

pr@seer.bio

Seer, Inc.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except share and per share amounts)

(unaudited)

Three Months Ended March 31,

2021

2020

Revenue

$

62 

$

177 

Operating expenses:

Research and development

6,227 

4,222 

Selling, general and administrative

10,333 

1,780 

Total operating expenses

16,560 

6,002 

Loss from operations

(16,498)

(5,825)

Other income (expense):

Interest income

69 

332 

Net loss

$

(16,429)

$

(5,493)

Net loss per share attributable to common stockholders, basic and diluted

$(0.27)

$(0.61)

Weighted-average common shares outstanding, basic and diluted

59,887,842

8,944,284

Seer, Inc.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands)

(unaudited)

March 31,

2021

2020

ASSETS

Current assets:

Cash and cash equivalents

$

445,763 

$

333,585 

Investments

85,379 

98,278 

Inventory

1,541 

551 

Other receivables

412 

163 

Other receivables, related parties

101 

99 

Prepaid expenses and other current assets

3,041 

452 

Total current assets

536,237 

433,128 

Property and equipment, net

8,682 

8,441 

Restricted cash

343 

343 

Other assets

377 

407 

TOTAL ASSETS

$

545,639 

$

442,319 

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current liabilities:

Accounts payable

$

1,933 

$

2,115 

Accrued expenses

5,021 

5,543 

Deferred revenue

256 

250 

Deferred rent, current

186 

186 

Total current liabilities

7,396 

8,094 

Deferred rent, net of current portion

1,884 

1,899 

Other noncurrent liabilities

589 

717 

Total liabilities

9,869 

10,710 

Commitments (Note 10)

Stockholders’ equity:

Preferred stock

— 

— 

Common stock

Additional paid-in capital

607,531 

486,915 

Accumulated other comprehensive income

28 

54 

Accumulated deficit

(71,790)

(55,361)

Total stockholders’ equity

535,770 

431,609 

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY

$

545,639 

$

442,319 



makes a similar move, sign up!

Other recent filings from the company include the following:

Departure of Directors or Certain - Oct. 13, 2021
Strategic Environmental & Energy Resources, Inc.'s Chief Financial Officer just cashed-in 10,000 options - Oct. 5, 2021

Auto Refresh

Feedback